1 Min Read
Aug 10 (Reuters) - Regen Biopharma Inc:
* Regen Biopharma Inc addresses potential impact of recent Bristol Myers Squibb’s $2.3 billion acquisition of IFM Therapeutics Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.